Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, gives a summary of the Phase II BREAKPOINT trial (NCT03463681) investigating cabozantinib after first-line immune checkpoint inhibitor (ICI) therapy in patients with advanced or unresectable renal cell carcinoma (RCC). Cabozantinib treatment has demonstrated prolonged survival in previously treated metastatic RCC patients. The primary endpoint of the BREAKPOINT study is progression-free survival (PFS). So far, the study, which has analyzed data from 22 patients, found that 22% of patients achieved a partial response and 5% of patients achieved stable disease. At a median follow-up of 7.2 months, the median PFS was 7.2 months. Thus far, cabozantinib therapy after first-line ICI therapy has demonstrated clinical activity and has been well-tolerated. This interview took place during the 2021 Genitourinary Cancers Symposium.
Dr Giuseppe Procopio, MD, has participated in an advisory role for AstraZeneca, Bayer, Ipsen, Janssen, Merckx, MSD Pharmaceuticals, Novartis, Pfizer and BMS.